摘要
目的评价胰高血糖素样肽-1受体激动剂(GLP-1RA)用于治疗术后体质量反弹(WR)或减重不足(IWL)患者的效果。方法使用计算检索Cochrane Library、Embase、Pubmed、中国知网、万方数据库中关于GLP-1RA治疗减重术后WR或IWL的文献,截止日期2022年10月。采用Cochrane偏倚风险评估工具独立评估RCTs的偏倚风险,使用Newcastle-Attawa Scale(NOS)评估观察性研究。每项研究都由2位评审员独立评估。必要时,通过求助于第3位评审员来解决分歧。采用SPSS 23.0对符合纳入与排除标准的文献进行分析。结果最终纳入9篇文献,其中6篇为回顾性队列研究,2篇为前瞻性队列研究,1篇为随机对照研究。共有631例患者接受了减重术后GLP-1RA治疗,涉及的GLP-1RA为利拉鲁肽与司美格鲁肽,研究时间为2011年至2022年。每项研究均报告了不同时间节点患者的体质量减轻情况。结论GLP-1RA治疗对减重术后WR或IWL患者的体质量减轻和改善并发症方面有效果,可以用于减重手术后效果不满意的患者。
Objective To evaluate the efficacy of GLP-1RA in patients with postoperative weight gain or weight loss.Methods We searched the Cochrane Library,Embase,Pubmed,CNKI and Wanfang databases for the articles about weight gain or underweight loss after GLP-1RA for bariatric surgery.The deadline was October 2022.Risk of bias in RCTs was assessed independently using the Cochrane risk of bias assessment tool,and observational studies were assessed using Newcastle-attawa Scale(Nos).Each study was independently evaluated by 2 reviewers.Resolve disagreements by turning to the third reviewer if necessary.SPSS 23.0 was used to analyze the literatures which met the inclusion and exclusion criteria.Results Nine Articles were included,of which 6 were retrospective cohort studies,2 were prospective cohort studies and 1 was randomized controlled study.A total of 631 patients were treated with post-bariatric GLP-1RA involving liraglutide versus SMECGLUTIDE during the study period from 2011 to 2022.Each study reported weight loss at different time points.Conclusion GLP-1RA is effective in reducing weight and improving complications in patients with weight gain or insufficient weight loss after bariatric surgery.GLP-1RA can be used in patients with unsatisfactory results after bariatric surgery.
出处
《浙江临床医学》
2023年第7期1008-1011,共4页
Zhejiang Clinical Medical Journal
基金
新疆维吾尔自治区自然科学基金资助项目(2022KY054)。
